The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Epilepsy is a common neurological disorder affecting millions globally.
• Current anti-seizure medications (ASMs) are ineffective for about one-third of patients and do not address underlying disease mechanisms.
• There is a critical need for novel therapeutic targets for causal epilepsy treatment.

Purpose of the Study:

• To review recent findings on P2X7 receptor (P2X7R) signaling in epilepsy.
• To explore the potential of P2X7R as a therapeutic target for epilepsy.
• To discuss P2X7R-based treatments as an adjunctive strategy for drug-refractory seizures.

Main Methods:

• Review of current literature on purinergic signaling and P2X7R in epilepsy.
• Analysis of studies investigating P2X7R protein levels in epilepsy models and human tissue.
• Examination of animal studies on the effects of P2X7R blockade on seizure activity and epilepsy phenotype.

Main Results:

• Purinergic signaling, particularly involving adenosine 5'-triphosphate (ATP), plays a role in seizure generation and epilepsy.
• P2X7R protein levels are elevated in epilepsy models and human epilepsy tissue.
• Blocking P2X7R has demonstrated efficacy in reducing seizure severity and the epileptic phenotype in animal studies.

Conclusions:

• P2X7R is a promising drug target for epilepsy treatment.
• Targeting P2X7R could offer a new adjunctive therapeutic strategy for drug-refractory epilepsy.
• Further research into P2X7R-based therapies is warranted for clinical application.